| 曹世钰,颜仕鹏,肖海帆,等.2022年湖南省肿瘤登记地区淋巴瘤流行特征及2012—2022年变化趋势分析[J].中国肿瘤,2026,35(7):532-538. |
| 2022年湖南省肿瘤登记地区淋巴瘤流行特征及2012—2022年变化趋势分析 |
| Epidemiological Characteristics of Lymphoma in Cancer Registration Areas of Hunan Province in 2022 and Temporal Trends from 2012 to 2022 |
| 投稿时间：2026-05-07 |
| DOI：10.11735/j.issn.1004-0242.2026.07.A005 |
|
 |
| 中文关键词: 淋巴瘤 发病率 死亡率 平均年度变化百分比 湖南 |
| 英文关键词:lymphoma incidence rate mortality rate average annual percentage change Hunan |
| 基金项目:湖南省卫生健康高层次人才重大科研专项（R2023117）；湖南省卫生健康委卫生健康科研课题（20257836）；湖南省肿瘤医院高层次人才五年支持计划（20250811-1001） |
|
| 摘要点击次数: 44 |
| 全文下载次数: 7 |
| 中文摘要: |
| 摘 要：［目的］ 分析2022年湖南省肿瘤登记地区淋巴瘤发病与死亡基本情况及2012—2022年变化趋势。［方法］ 收集湖南省肿瘤登记地区2012—2022年淋巴瘤发病与死亡数据，计算2022年淋巴瘤的发病和死亡粗率、标化率以及累积率等指标。采用 Joinpoint回归模型分析时间趋势，计算标化率的平均年度变化百分比（average annual percentage change，AAPC），并进一步探究年龄分布特征。［结果］ 2022年总体粗发病率为11.74/10万（中国人口标化发病率为7.64/10万）、粗死亡率为5.53/10万（中国人口标化死亡率为3.06/10万）。2022年湖南省肿瘤登记地区淋巴瘤的所有发病和死亡指标均呈现男性显著高于女性、城市显著高于农村地区的特征。2022年湖南省肿瘤登记地区淋巴瘤年龄别发病率25岁前较低（1岁以下年龄组高于1~24岁年龄段），25岁后随年龄增长上升，75~79岁年龄组达峰值，80岁后下降；年龄别死亡率35岁后逐步上升，75~79岁年龄组达峰值。2012—2022年淋巴瘤中国人口标化发病率（AAPC=4.52%）与中国人口标化死亡率（AAPC=4.53%）均显著上升，其中女性发病率（AAPC=5.91%）、农村地区发病率（AAPC=8.18%）上升幅度更突出，男女性死亡率及农村地区死亡率亦呈显著上升趋势。［结论］ 2012—2022年湖南省肿瘤登记地区淋巴瘤发病与死亡率整体呈上升趋势，男性、城市地区水平更高，但女性发病率、农村地区发病率上升更快，需针对重点人群加强防控。 |
| 英文摘要: |
| Abstract：［Purpose］ To analyze the incidence and mortality of lymphoma in Hunan cancer registration areas in 2022 and the temporal trends from 2012 to 2022.［Methods］ Data on lymphoma incidence and mortality from 103 cancer registration points in Hunan Province from 2012 to 2022 were collected. Crude incidence rate， crude mortality rate， age-standardized rates and cumulative rate of 0-74 years old in 2022 were calculated. Joinpoint regression model was used to analyze the temporal trends， and the average annual percentage change (AAPC) of age-standardized rates was estimated. The age-specific distribution characteristics were further explored. ［Results］ In 2022， the overall incidence rate was 11.74/105 (age-standardized incidence rate by Chinese standard population：7.64/105)， and the overall mortality rate was 5.53/105 (age-standardized mortality rate by Chinese standard population：3.06/105). All incidence and mortality indicators were significantly higher in males than in females and in urban areas than in rural areas. The age-specific incidence rate was low before 25 years old (the rate in the <1-year-old group was higher than that in the 1-24-year-old group)， increased with age after 25 years old， peaked at 75-79 years old， and declined after 80 years old. The age-specific mortality rate increased gradually after 35 years old and peaked at 75-79 years old. From 2012 to 2022， both the age-standardized incidence rate (AAPC=4.52%) and age-standardized mortality rate (AAPC=4.53%) increased significantly. Among them， the increase in incidence was more pronounced in females(AAPC=5.91%) and in rural areas (AAPC=8.18%). Mortality also rose significantly in both sexes and in rural areas.［Conclusion］ From 2012 to 2022， the overall incidence and mortality of lymphoma in Hunan cancer registration areas showed an upward trend. The levels were higher in males and in urban areas， but the incidence increased faster in females and in rural areas. Targeted prevention and control measures should be strengthened for key populations. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |